Tags

Type your tag names separated by a space and hit enter

Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial.
Lipids Health Dis. 2020 Jun 20; 19(1):143.LH

Abstract

BACKGROUND

Amaranth seed oil (ASO) and rapeseed oil (RSO) are functional foods that display antioxidant and hepatoprotective properties. These oils are also known to lower glucose and cholesterol levels. The current study compared the effects exerted by RSO and ASO on weight loss and metabolic parameters during a 3-week body mass reduction program.

METHODS

Eighty-one obese subjects (BMI > 30 kg/m2), aged 25-70 years, were enrolled in a 3-week body mass reduction program based on a calorie-restricted diet and physical activity. Participants were randomly categorized into an AO group (administered 20 mL/d of ASO), a RO group (administered 20 mL/d of RSO), and a C group (control; untreated). Anthropometric and metabolic parameters were measured at baseline and endpoint.

RESULTS

Significant decreases in weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), fat mass (FM), lean body mass (LBM), visceral fat mass (VFM), and total body water (TBW%) were observed in all groups (P < 0.05). No significant improvements were observed in the clinical parameters of group C. Fasting insulin (Δ - 5.9, and Δ - 5.7) and homeostatic model assessment of insulin resistance (HOMA-IR) (Δ - 1.1 and Δ - 0.5) were decreased in both RO and AO groups, respectively. Fasting glucose (Δ -8.5; P = 0.034), total cholesterol (Δ -14.6; P = 0.032), non-HDL cholesterol (Δ 15.9; P = 0.010), TG/HDL ratio (Δ -0.6; P = 0.032), LDL cholesterol (Δ -12.3; P = 0.042), and triglycerides (Δ -6.5; P = 0.000) were significantly improved in the AO group, compared to the RO group.

CONCLUSIONS

The 3-week body mass reduction intervention caused a significant reduction in the weight, BMI, WC, HC, FM, and VFM of all groups. Except for HOMA-IR, there were no statistical differences between the clinical parameters of all groups. However, a trend toward improved insulin levels and HDL% was noticeable in AO and RO. Therapies involving edible oils with high nutritional value, such as RSO and ASO, show potential for improving metabolic measurements during body mass reduction programs. Thus, obese patients undertaking weight reduction programs may benefit from RSO and ASO supplementation.

TRIAL REGISTRATION

retrospectively registered, DRKS00017708.

Authors+Show Affiliations

Department of Obesity and Metabolic Disorders Treatment and Clinical Dietetics, Karol Marcinkowski University of Medical Sciences, ul. Szamarzewskiego 82/84, 60-569, Poznań, Polska, Poland. mmoszak@ump.edu.pl.Department of Gastroenterology, Dietetics and Internal Medicine, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.Centre of Pulmonology and Thoracic Surgery, Poznan, Poland.Department of Gastroenterology, Dietetics and Internal Medicine, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.Department of Obesity and Metabolic Disorders Treatment and Clinical Dietetics, Karol Marcinkowski University of Medical Sciences, ul. Szamarzewskiego 82/84, 60-569, Poznań, Polska, Poland.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

32563253

Citation

Moszak, Małgorzata, et al. "Comparison of the Effect of Rapeseed Oil or Amaranth Seed Oil Supplementation On Weight Loss, Body Composition, and Changes in the Metabolic Profile of Obese Patients Following 3-week Body Mass Reduction Program: a Randomized Clinical Trial." Lipids in Health and Disease, vol. 19, no. 1, 2020, p. 143.
Moszak M, Zawada A, Juchacz A, et al. Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial. Lipids Health Dis. 2020;19(1):143.
Moszak, M., Zawada, A., Juchacz, A., Grzymisławski, M., & Bogdański, P. (2020). Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial. Lipids in Health and Disease, 19(1), 143. https://doi.org/10.1186/s12944-020-01330-7
Moszak M, et al. Comparison of the Effect of Rapeseed Oil or Amaranth Seed Oil Supplementation On Weight Loss, Body Composition, and Changes in the Metabolic Profile of Obese Patients Following 3-week Body Mass Reduction Program: a Randomized Clinical Trial. Lipids Health Dis. 2020 Jun 20;19(1):143. PubMed PMID: 32563253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial. AU - Moszak,Małgorzata, AU - Zawada,Agnieszka, AU - Juchacz,Aldona, AU - Grzymisławski,Marian, AU - Bogdański,Paweł, Y1 - 2020/06/20/ PY - 2020/01/26/received PY - 2020/06/17/accepted PY - 2020/6/22/entrez PY - 2020/6/22/pubmed PY - 2021/4/20/medline KW - Amaranth seed oil KW - Body composition KW - Metabolic profile KW - Rapeseed oil KW - Weight loss SP - 143 EP - 143 JF - Lipids in health and disease JO - Lipids Health Dis VL - 19 IS - 1 N2 - BACKGROUND: Amaranth seed oil (ASO) and rapeseed oil (RSO) are functional foods that display antioxidant and hepatoprotective properties. These oils are also known to lower glucose and cholesterol levels. The current study compared the effects exerted by RSO and ASO on weight loss and metabolic parameters during a 3-week body mass reduction program. METHODS: Eighty-one obese subjects (BMI > 30 kg/m2), aged 25-70 years, were enrolled in a 3-week body mass reduction program based on a calorie-restricted diet and physical activity. Participants were randomly categorized into an AO group (administered 20 mL/d of ASO), a RO group (administered 20 mL/d of RSO), and a C group (control; untreated). Anthropometric and metabolic parameters were measured at baseline and endpoint. RESULTS: Significant decreases in weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), fat mass (FM), lean body mass (LBM), visceral fat mass (VFM), and total body water (TBW%) were observed in all groups (P < 0.05). No significant improvements were observed in the clinical parameters of group C. Fasting insulin (Δ - 5.9, and Δ - 5.7) and homeostatic model assessment of insulin resistance (HOMA-IR) (Δ - 1.1 and Δ - 0.5) were decreased in both RO and AO groups, respectively. Fasting glucose (Δ -8.5; P = 0.034), total cholesterol (Δ -14.6; P = 0.032), non-HDL cholesterol (Δ 15.9; P = 0.010), TG/HDL ratio (Δ -0.6; P = 0.032), LDL cholesterol (Δ -12.3; P = 0.042), and triglycerides (Δ -6.5; P = 0.000) were significantly improved in the AO group, compared to the RO group. CONCLUSIONS: The 3-week body mass reduction intervention caused a significant reduction in the weight, BMI, WC, HC, FM, and VFM of all groups. Except for HOMA-IR, there were no statistical differences between the clinical parameters of all groups. However, a trend toward improved insulin levels and HDL% was noticeable in AO and RO. Therapies involving edible oils with high nutritional value, such as RSO and ASO, show potential for improving metabolic measurements during body mass reduction programs. Thus, obese patients undertaking weight reduction programs may benefit from RSO and ASO supplementation. TRIAL REGISTRATION: retrospectively registered, DRKS00017708. SN - 1476-511X UR - https://www.unboundmedicine.com/medline/citation/32563253/Comparison_of_the_effect_of_rapeseed_oil_or_amaranth_seed_oil_supplementation_on_weight_loss_body_composition_and_changes_in_the_metabolic_profile_of_obese_patients_following_3_week_body_mass_reduction_program:_a_randomized_clinical_trial_ L2 - https://lipidworld.biomedcentral.com/articles/10.1186/s12944-020-01330-7 DB - PRIME DP - Unbound Medicine ER -